Oncolytics Biotech Stock Forecast

Buy candidate since Jun 16, 2026

The Oncolytics Biotech Inc. stock price gained 11.68% on the last trading day (Tuesday, 16th Jun 2026), rising from $0.85 to $0.95. During the last trading day the stock fluctuated 9.08% from a day low at $0.88 to a day high of $0.96. The price has fallen in 6 of the last 10 days but is still up by 2.36% over the past 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 1 million more shares were traded than the day before. In total, 3 million shares were bought and sold for approximately $2.44 million.

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -10.90% during the next 3 months and, with a 90% probability hold a price between $0.617 and $0.95 at the end of this 3-month period.

ONCY Signals & Forecast

The Oncolytics Biotech Inc. stock holds buy signals from both short and long-term Moving Averages giving a positive forecast for the stock, but the stock has a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections down, there will be some support from the lines at $0.84 and $0.87. A breakdown below any of these levels will issue sell signals. A buy signal was issued from a pivot bottom point on Wednesday, June 10, 2026, and so far it has risen 18.67%. Further rise is indicated until a new top pivot has been found. Volume is rising along with the price. This is considered to be a good technical signal. Some negative signals were issued as well, and these may have some influence on the near short-term development. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD).

Support, Risk & Stop-loss for Oncolytics Biotech Inc. stock

Oncolytics Biotech Inc. finds support from accumulated volume at $0.93 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock may move much during the day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $0.0799 between high and low, or 9.08%. For the last week, the stock has had daily average volatility of 6.93%.

Our recommended stop-loss: $0.91 (-3.92%) (This stock has high daily movements and this gives high risk. There is a buy signal from a pivot bottom found 4 days ago.)

Trading Expectations (ONCY) For The Upcoming Trading Day Of Wednesday 17th

For the upcoming trading day on Wednesday, 17th we expect Oncolytics Biotech Inc. to open at $0.93, and during the day (based on 14 day Average True Range), to move between $0.91 and $0.99, which gives a possible trading interval of +/-$0.0753 (+/-8.26%) up or down from last closing price. If Oncolytics Biotech Inc. takes out the full calculated possible swing range there will be an estimated 8.26% move between the lowest and the highest trading price during the day.

Since the stock is closer to the resistance from accumulated volume at $0.97 (2.02%) than the support at $0.93 (2.31%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.

Is Oncolytics Biotech Inc. stock A Buy?

Several short-term signals are positive, despite the stock being in a falling trend, we conclude that the current level may hold a buying opportunity as there is a fair chance for stock to perform well in the short-term. We have upgraded our analysis conclusion for this stock since the last evaluation from a Sell to a Buy candidate.

Current score: 3.627 Buy Candidate Upgraded

Predicted Fair Opening Price

Predicted fair opening price on June 17, 2026 - $0.93 ( 2.07%).

Want to trade but not sure how? Our step-by-step guide can help.
Skip the guide? Open account with our trusted broker*
*Your capital is at risk